Delcath Systems

company

About

Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$6.20M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 1987
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
fra:DV3P
Legal Name
Delcath Systems, Inc.

Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer. Its proprietary product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
11
$149.60M
Delcath Systems has raised a total of $149.60M in funding over 2 rounds. Their latest funding was raised on Dec 8, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 8, 2022 Post-IPO Equity $6.20M Detail
Jul 18, 2022 Post-IPO Equity $5M Detail
Aug 9, 2021 Post-IPO Debt $20M 1 Avenue Capital Group Detail
Dec 11, 2020 Post-IPO Equity $22.20M Detail
Jul 23, 2019 Post-IPO Equity $20M Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Delcath Systems is funded by 2 investors. Avenue Capital Group and Silicon Valley Bank are the most recent investors.
Investor Name Lead Investor Funding Round
Avenue Capital Group Yes Post-IPO Debt
Silicon Valley Bank Yes Post-IPO Debt

Employee Profiles

Number of Employee Profiles
6
Delcath Systems has 6 current employee profiles, including Employee John Sylvester
Employee
Executive
Executive
Employee